Who is eligible for clinical trial NCT06087458?

Participants must meet protocol criteria for Age-Related Macular Degeneration. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06087458 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-12

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (NCT06087458)

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Perceive Biotherapeutics, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (3 items).

Location: Retina Macula Institute of AZ — Scottsdale, Arizona

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Are ≥60 years of age at the time of consent.
Are willing and able to understand and provide written informed consent.
Are willing and able to return for scheduled treatment and follow-up examinations.
Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
Absence of signs of non-exudative MNV.
Additional Ocular Inclusion Criteria for both eyes.
Meet certain genotype criteria for risk of AMD.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
Additional Systemic, Ocular, and Genetic Exclusion Criteria.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (16 Sites)

Retina Macula Institute of AZ — Scottsdale, Arizona
Retina Consultants San Diego — Poway, California
Retinal Consultants Medical Group — Sacramento, California
Ophthalmic Consultants of Boston — Boston, Massachusetts
The Retina Institute — St Louis, Missouri
Mid Atlantic Retina — Cherry Hill, New Jersey
Retina Northwest — Portland, Oregon
Black Hills Regional Eye Institute — Rapid City, South Dakota
Austin Research Center for Retina — Austin, Texas
Star Retina — Fort Worth, Texas
Retina Center of Texas — Southlake, Texas
University of Utah John A. Moran Eye Center — Salt Lake City, Utah
Sydney Retina Clinic and Day Surgery — Sydney, New South Wales
Cerulea Clinical Trials — East Melbourne, Victoria
Rambam Medical Center — Haifa,
Tel-Aviv Sourasky Medical Center, Ophthalmology Division — Tel Aviv,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗